Our NK immune cell-based cancer therapy faced challenges during its development and efficacy evaluation. To address these issues, we explored various platforms and discovered the Lambda Biologics platform, which we utilized for efficacy testing.
Contrary to our initial expectations, the platform provided a wealth of additional information. Beyond simply evaluating efficacy, we were able to establish optimal conditions to maximize the therapeutic potential of our NK immune cell-based therapy.
Based on these results, we were able to enhance our NK immune cell therapy, making the Lambda Biologics platform an effective tool for drug development and optimization.